Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Short term Debt (2021 - 2025)

Bioregenx has reported Short term Debt over the past 5 years, most recently at $1.0 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 13.58% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, up 13.58%, while the annual FY2025 figure was $1.0 million, 13.58% up from the prior year.
  • Short term Debt for Q4 2025 was $1.0 million at Bioregenx, down from $1.0 million in the prior quarter.
  • Over five years, Short term Debt peaked at $1.0 million in Q3 2025 and troughed at $2163.0 in Q4 2021.
  • A 5-year average of $567743.4 and a median of $850152.0 in 2024 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: soared 20210.65% in 2024 and later increased 3.69% in 2025.
  • Year by year, Short term Debt stood at $2163.0 in 2021, then skyrocketed by 93.67% to $4189.0 in 2022, then surged by 8868.27% to $375681.0 in 2023, then surged by 135.11% to $883271.0 in 2024, then rose by 13.58% to $1.0 million in 2025.
  • Business Quant data shows Short term Debt for BRGX at $1.0 million in Q4 2025, $1.0 million in Q3 2025, and $970117.0 in Q2 2025.